By Fineline Cube Abbisko Therapeutics Co., Ltd. (HKG: 2256) announced that the European Medicines Agency (EMA) has granted Orphan Drug Designation (ODD) for its novel small-molecule FGFR4 inhibitor irpagratinib for the treatment of hepatocellular carcinoma (HCC).
Regulatory Milestone
| Item | Detail |
|---|---|
| Agency | European Medicines Agency (EMA) |
| Designation | Orphan Drug Designation (ODD) |
| Product | Irpagratinib (FGFR4 inhibitor) |
| Indication | Hepatocellular carcinoma (HCC) |
| Intellectual Property | Global patents held by Abbisko Therapeutics |
| Previous Designations | FDA ODD & Fast Track; NMPA Breakthrough Therapy |
Drug Profile & Mechanism of Action
- Molecule: Novel small-molecule FGFR4 inhibitor (oral)
- Target: Fibroblast Growth Factor Receptor 4 (FGFR4) pathway
- Patient Population: Advanced HCC patients with FGF19 overexpression
- Innovation: Selective inhibition of FGFR4 signaling specifically in FGF19-overexpressing tumors
- Intellectual Property: Global patents covering compound structure and therapeutic use
Clinical Development Status
| Trial Phase | Regimen | Patient Population | Status |
|---|---|---|---|
| First-line | Combination therapy | Advanced HCC with FGF19 overexpression | Ongoing global trials |
| Second-line+ | Monotherapy | Advanced HCC with FGF19 overexpression | Ongoing global trials |
| Combination Partners | Targeted agents + Immuno-oncology drugs | Advanced HCC with FGF19 overexpression | Multiple trials active |
Clinical Evidence: Previous studies demonstrated favorable safety, tolerability, and antitumor activity both as monotherapy and in combination regimens for advanced HCC patients with FGF19 overexpression.
Regulatory Progress Timeline
- U.S. FDA: Previously granted Orphan Drug Designation (ODD) and Fast Track Designation (FTD)
- China NMPA: Previously granted Breakthrough Therapy Designation (BTD)
- EMA: Current Orphan Drug Designation (ODD) completes triad of major regulatory incentives
The EMA ODD provides Abbisko with 10 years of market exclusivity in the EU upon approval, protocol assistance, and reduced regulatory fees.
Market Impact & Strategic Significance
- HCC Treatment Landscape: With limited effective therapies for advanced HCC and poor prognosis, targeted treatments for molecularly-defined subpopulations represent significant unmet need
- Commercial Opportunity: FGF19 overexpression occurs in approximately 30% of HCC cases, representing a substantial addressable patient population
- Competitive Advantage: Irpagratinib’s triple regulatory designation status (FDA, NMPA, EMA) accelerates development timeline and enhances commercial prospects
- Global Strategy: Ongoing global clinical trials position Abbisko for simultaneous regulatory submissions across major markets
Forward‑Looking Statements
This brief contains forward-looking statements regarding regulatory designations, clinical development, and commercial potential for irpagratinib. Actual results may differ due to risks including clinical trial outcomes, regulatory decisions, and competitive dynamics.-Fineline Info & Tech